Alnylam: Barclays Global Healthcare Conference (Alnylam) - Mar 13, 2013 - "ALN-PCS Phase I Study Results"; "Pharmacodynamics and Clinical Efficacy"; "PCSK9 knockdown and LDL-C reduction after single dose without statins"; "Randomized, placebo controlled, single dose escalation study in healthy volunteers with elevated LDL (n=32)"; "Rapid, dose-dependent, and durable knockdown of PCSK9 of up to 84% with mean lowering of 68% at 0.4 mg/kg group (p<0.0001)"; "Major reductions in LDL-C of up to 50% with mean lowering of 41% at 0.4 mg/kg group (p<0.01)"
P1 data • Dyslipidemia
|